Drugs / aH5N6c
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05874713 | Jun 2023 → Apr 2024 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 2 | NCT05422326 | Jul → Oct 2022 | avian influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aH5N6c | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05874713 ↗ |
| Modality | Vaccine | “MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine” NCT05422326 ↗ |
| Route | Intramuscular | “for intramuscular (IM) administration” NCT05422326 ↗ |